Stephens lowered the firm’s price target on Health Catalyst (HCAT) to $5 from $7 and keeps an Equal Weight rating on the shares. While “encouraged” by the company’s continued focus on growing higher-margin, recurring technology revenue, the firm notes that the company’s lighter Q1 outlook lagged consensus and implies a material top- and bottom-line ramp in the second half.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT:
- Health Catalyst’s Earnings Call Highlights Robust Growth and Strategic Challenges
- Health Catalyst announces multiyear agreement with Signature Health
- Health Catalyst price target lowered to $10 from $13 at BTIG
- Health Catalyst’s Promising Financial Trajectory and Growth Potential Justifies Buy Rating
- Health Catalyst’s Strategic Growth and Robust Technology Segment Drive Buy Rating